FIELD: medicine.
SUBSTANCE: there are offered specific antibodies linked at least with KIR2DL1, KIR2DL2, KIR2DL3 human receptor, neutralise KIR-mediated NK cytolergy inhibition in relation to Cw3+ or Cw4+ target-cells. There are described: B-lymphocyte hybrid cell for producing the antibodies, versions of the method for producing the antibody, as well as a method for detecting a NK-cell, a method for purifying the NK-cells with the use of the antibody and versions of the pharmaceutical antibody composition. Using the antibody for preparing a medicinal agent is offered.
EFFECT: use of the invention provides producing the antibody which controls NK cytolergy of various types, intensifies cytotoxicity, increases NK cytolergy or cytotoxicity in individuals.
63 cl, 13 dwg, 3 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION AND METHOD FOR CONTROL OF ACTIVITY OF NATURAL KILLER CELLS | 2004 |
|
RU2376315C2 |
| METHODS AND COMPOSITIONS FOR IMPROVING EFFECTIVENESS OF ANTIBODY FOR MEDICAL APPLICATION WITH USING COMPOUNDS POTENTIATING NK-CELLS | 2004 |
|
RU2396981C2 |
| ANTIBODY CAPABLE OF BINDING WITH KIR2DL 1,-2,-3 RECEPTORS BUT NOT WITH KIR2DS4 RECEPTOR AND THERAPEUTIC APPLICATION THEREOF | 2005 |
|
RU2410396C2 |
| METHOD FOR ACTIVATION OF CYTOTOXIC LYMPHOCYTES | 2019 |
|
RU2751837C2 |
| CHIMERIC ANTIGEN RECEPTORS WITH MUTATED CD28 COSTIMULATION DOMAINS | 2018 |
|
RU2800922C2 |
| SELECTIVE ELIMINATION OF EROSION CELLS | 2012 |
|
RU2617056C2 |
| ANTI-CANCER TARGETED IMMUNOTHERAPY WITH APPLICATION OF IL-12 | 2015 |
|
RU2689160C2 |
| COMPOSITIONS AND METHODS USED FOR ASSESSING CYTOTOXICITY OF SINGLE CELLS | 2009 |
|
RU2532228C2 |
| IMMUNOSTIMULATORY MONOCLONAL ANTIBODIES | 1995 |
|
RU2155190C2 |
| METHODS OF APPLYING OF APO-2L-RECEPTORS AGONISTS AND NK-CELLS ACTIVATORS | 2005 |
|
RU2395294C2 |
